<DOC>
	<DOCNO>NCT02750618</DOCNO>
	<brief_summary>UX023-CL205 multicenter , open-label , Phase 2 study child 1 4 year old XLH ass safety , PD , efficacy KRN23 administer via subcutaneous ( SC ) injection every 2 week ( Q2W ) total 64 week .</brief_summary>
	<brief_title>Study Safety , Pharmacodynamics Efficacy KRN23 Children From 1 4 Years Old With X-linked Hypophosphatemia ( XLH )</brief_title>
	<detailed_description>The study enroll approximately 10 pediatric subject 1 4 year old , inclusive , confirmed diagnosis XLH radiographic evidence rickets . Subjects discontinue oral phosphate active vitamin D therapy initial Screening duration study . All subject receive treatment KRN23 . Safety , PD , pre-dose KRN23 concentration , efficacy measure ( rickets , growth , functional outcome ) evaluate throughout study . Radiographs take assess rickets periodically throughout study duration .</detailed_description>
	<mesh_term>Familial Hypophosphatemic Rickets</mesh_term>
	<mesh_term>Hypophosphatemia</mesh_term>
	<criteria>1 . Male female , age â‰¥1 year &lt; 5 year 2 . Diagnosis XLH support ONE follow Confirmed PHEX mutation patient directly relate family member appropriate Xlinked inheritance Serum FGF23 level &gt; 30 pg/mL Kainos assay 3 . Biochemical finding associate XLH include : Serum phosphorus &lt; 3.0 mg/dL ( 0.97 mmol/L ) Serum creatinine within ageadjusted normal range 4 . Radiographic evidence rickets 5 . Willing provide access prior medical record collection historical growth , biochemical , radiographic data disease history 6 . Provide write informed consent legally authorize representative nature study explain , prior researchrelated procedure 7 . Must , opinion investigator , willing able complete aspect study , adhere study visit schedule , comply assessment 1 . Unwilling stop treatment oral phosphate and/or pharmacologic vitamin D metabolite analog ( e.g . calcitriol , alfacalcidol ) screen period duration study 2 . Planned recommend orthopedic surgery include staple , 8plates osteotomy , within clinical trial period 3 . Hypocalcemia hypercalcemia , define serum calcium level outside ageadjusted normal limit 4 . Presence history condition , view investigator , place subject high risk poor treatment compliance complete study 5 . Presence concurrent disease condition would interfere study participation affect safety 6 . History recurrent infection predisposition infection , know immunodeficiency 7 . Use investigational product investigational medical device within 30 day prior screen , requirement investigational agent prior completion schedule study assessment</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>4 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>